Warfarin dosing in patients with impaired kidney function

American Journal of Kidney Diseases

Volumn 56, Issue 5, 2010, Pages 823-831

  Limdi, Nita A ^a,b   Limdi, Mohit A ^a,c   Cavallari, Larisa ^d   Anderson, Aaron M ^a   Crowley, Michael R ^e   Baird, Melissa F ^b   Allon, Michael ^f   Beasley, T Mark ^b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Altamont School   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

CYP2C9; dose adjustment; kidney impairment; pharmacogenetics; VKORC1; Warfarin

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; VKORC1 PROTEIN; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; DNA; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ANTICOAGULATION; ARTICLE; ASIAN; BODY MASS; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; EUROPEAN AMERICAN; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HISPANIC; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RACE DIFFERENCE; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE; SMOKING; VITAMIN INTAKE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CROSS-SECTIONAL STUDIES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA; WARFARIN; CYTOCHROME P-450 CYP2C9; VITAMIN K EPOXIDE REDUCTASES;

EID: 77958511313     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.05.023     Document Type: Article

References (57)

1. J. Coresh, E. Selvin, and L.A. Stevens Prevalence of chronic kidney disease in the United States JAMA 298 17 2007 2038 2047 (Pubitemid 350074801)
2. L.D. Bash, J. Coresh, and A. Kottgen Defining incident chronic kidney disease in the research setting: the ARIC Study Am J Epidemiol 170 4 2009 414 424
3. D.E. Weiner Public health consequences of chronic kidney disease Clin Pharmacol Ther 86 5 2009 566 569
4. D.E. Weiner, S. Tabatabai, and H. Tighiouart Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease Am J Kidney Dis 48 2006 392 401
5. H. Reinecke, E. Brand, and R. Mesters Dilemmas in the management of atrial fibrillation in chronic kidney disease J Am Soc Nephrol 20 4 2009 705 711
6. F. Knauf, and P.S. Aronson ESRD as a window into America's cost crisis in health care J Am Soc Nephrol 20 10 2009 2093 2097
7. S. Anderson, J.B. Halter, and W.R. Hazzard Prediction, progression, and outcomes of chronic kidney disease in older adults J Am Soc Nephrol 20 6 2009 1199 1209
8. Y. Zhang, L. Zhang, and S. Abraham Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications Clin Pharmacol Ther 85 3 2009 305 311
9. T.D. Nolin Altered nonrenal drug clearance in ESRD Curr Opin Nephrol Hypertens 17 6 2008 555 559
10. J. Michaud, J. Naud, and J. Chouinard Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure J Am Soc Nephrol 17 11 2006 3041 3048
11. A.W. Dreisbach, and J.J. Lertora The effect of chronic renal failure on drug metabolism and transport Expert Opin Drug Metab Toxicol 4 8 2008 1065 1074
12. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 6 suppl 2008 160S 198S (Pubitemid 351892967)
13. D.S. Budnitz, N. Shehab, S.R. Kegler, and C.L. Richards Medication use leading to emergency department visits for adverse drug events in older adults Ann Intern Med 147 11 2007 755 765
14. A.W. Dreisbach, S. Japa, and A.B. Gebrekal Cytochrome P4502C9 activity in end-stage renal disease Clin Pharmacol Ther 73 5 2003 475 477
15. M.J. Elliott, D. Zimmerman, and R.M. Holden Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates Am J Kidney Dis 50 3 2007 433 440
16. S. Genovesi, A. Vincenti, and E. Rossi Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients Am J Kidney Dis 51 2 2008 255 262
17. N.A. Limdi, T.M. Beasley, and M.F. Baird Kidney function influences warfarin responsiveness and hemorrhagic complications J Am Soc Nephrol 20 2009 912 921
18. N.A. Limdi, T.M. Beasley, and M.R. Crowley VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Pharmacogenomics 9 10 2008 1445 1458
19. K.M. Momary, N.L. Shapiro, M.A. Viana, E.A. Nutescu, C.M. Helgason, and L.H. Cavallari Factors influencing warfarin dose requirements in African-Americans Pharmacogenomics 8 11 2007 1535 1544
20. J.O. Miners, and D.J. Birkett Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45 6 1998 525 538
21. A.E. Rettie, and J.P. Jones Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics Annu Rev Pharmacol Toxicol 45 2005 477 494
22. A.S. Levey, J. Coresh, and T. Greene Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate Ann Intern Med 145 4 2006 247 254
23. A.S. Levey, J. Coresh, and E. Balk National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2 2003 137 147
24. S.M. Huang, R. Temple, S. Xiao, L. Zhang, and L.J. Lesko When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective Clin Pharmacol Ther 86 5 2009 475 479
25. N. Limdi, J. Goldstein, J. Blaisdell, T. Beasley, C. Rivers, and R. Acton Influence of CYP2C9 genotype on warfarin dose among African American and European Americans Pers Med 4 2 2007 157 169
26. N.A. Limdi, G. McGwin, and J.A. Goldstein Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin Clin Pharmacol Ther 83 2 2008 312 321
27. A.W. Dreisbach, and J.J. Lertora The effect of chronic renal failure on hepatic drug metabolism and drug disposition Semin Dial 16 1 2003 45 50
28. F. Leblond, C. Guevin, C. Demers, I. Pellerin, M. Gascon-Barre, and V. Pichette Downregulation of hepatic cytochrome P450 in chronic renal failure J Am Soc Nephrol 12 2 2001 326 332
29. A.C. Elston, M.K. Bayliss, and G.R. Park Effect of renal failure on drug metabolism by the liver Br J Anaest 71 2 1993 282 290
30. T.D. Nolin, R.F. Frye, and P. Le ESRD impairs nonrenal clearance of fexofenadine but not midazolam J Am Soc Nephrol 20 10 2009 2269 2276
31. M.D. Ezekowitz, S. Connolly, and A. Parekh Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 157 5 2009 805 810 810 e801-802
32. A.M. Young, L.J. Billingham, and G. Begum Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial Lancet 373 9663 2009 567 574
33. C. Wanner, V. Krane, and W. Marz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 3 2005 238 248 (Pubitemid 41058323)
34. G.F. Strippoli, S.D. Navaneethan, and D.W. Johnson Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 336 7645 2008 645 651
35. L.S. Kaminsky, and Z.Y. Zhang Human P450 metabolism of warfarin Pharmacol Ther 73 1 1997 67 74
36. A.E. Rettie, K.R. Korzekwa, and K.L. Kunze Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions Chem Res Toxicol 5 1 1992 54 59
37. W.J. Spruill, W.E. Wade, and H.H. Cobb III Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function Clin Pharmacol Ther 86 5 2009 468 470
38. L.A. Stevens, and A.S. Levey Use of the MDRD Study equation to estimate kidney function for drug dosing Clin Pharmacol Ther 86 5 2009 465 467
39. L.A. Stevens, and A.S. Levey Measured GFR as a confirmatory test for estimated GFR J Am Soc Nephrol 20 11 2009 2305 2313
40. A.K. Jain, I. McLeod, and C. Huo When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase Kidney Int 76 3 2009 318 323
41. A.S. Levey, A.C. Schoolwerth, N.R. Burrows, D.E. Williams, K.R. Stith, and W. McClellan Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention Am J Kidney Dis 53 3 2009 522 535
42. L.A. Stevens, and A.S. Levey Impact of reporting estimated glomerular filtration rate: it's not just about us Kidney Int 76 3 2009 245 247
43. W.G. Miller Reporting estimated GFR: a laboratory perspective Am J Kidney Dis 52 4 2008 645 648
44. B.K. Meijers, B. Bammens, K. Verbeke, and P. Evenepoel A review of albumin binding in CKD Am J Kidney Dis 51 5 2008 839 850
45. E. Selvin, A. Kottgen, and J. Coresh Kidney function estimated from serum creatinine and cystatin C and peripheral arterial disease in NHANES 1999-2002 Eur Heart J 30 15 2009 1918 1925
46. N. Taglieri, W. Koenig, and J.C. Kaski Cystatin C and cardiovascular risk Clin Chem 55 11 2009 1932 1943
47. R.N. Foley, C. Wang, J.J. Snyder, and A.J. Collins Cystatin C levels in U.S. adults, 1988-1994 versus 1999-2002: NHANES Clin J Am Soc Nephrol 4 5 2009 965 972
48. L.A. Stevens, J. Coresh, and C.H. Schmid Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD Am J Kidney Dis 51 3 2008 395 406
49. M. Tidman, P. Sjostrom, and I. Jones A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two Nephrol Dial Transplant 23 1 2008 154 160
50. A.S. Levey, L.A. Stevens, and C.H. Schmid A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
51. Q.L. Zhang, and D. Rothenbacher Prevalence of chronic kidney disease in population-based studies: systematic review BMC Public Health 8 2008 117
52. K. Wattanakit, M. Cushman, C. Stehman-Breen, S.R. Heckbert, and A.R. Folsom Chronic kidney disease increases risk for venous thromboembolism J Am Soc Nephrol 19 1 2008 135 140
53. K. Wattanakit, A.R. Folsom, E. Selvin, J. Coresh, A.T. Hirsch, and B.D. Weatherley Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study J Am Soc Nephrol 18 2 2007 629 636 (Pubitemid 46193329)
54. D.E. Weiner, H. Tighiouart, and M.G. Amin Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies J Am Soc Nephrol 15 5 2004 1307 1315
55. H. Watanabe, T. Watanabe, S. Sasaki, K. Nagai, D.M. Roden, and Y. Aizawa Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study Am Heart J 158 4 2009 629 636
56. A. Mahajan, J. Qiu, and P.C. Stark Prevalence of ICD-9-CM codes for chronic kidney disease in individuals with cardiovascular disease risk factors J Nephrol 22 4 2009 523 533
57. D. Lloyd-Jones, R. Adams, and M. Carnethon Heart disease and stroke statistics2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 3 2009 480 486